| Tysabri (natalizumab) / Biogen, Royalty |
NCT00097760: Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis |
|
|
| Completed | 2 | 110 | US | Natalizumab, Tysabri, Placebo | Biogen, Elan Pharmaceuticals | Multiple Sclerosis, Relapsing-Remitting | 03/04 | 03/04 | | |
NCT00083759: Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate |
|
|
| Terminated | 2 | 299 | US, Canada | natalizumab, TYSABRI, placebo | Biogen, Elan Pharmaceuticals | Rheumatoid Arthritis | 02/05 | | | |
NCT00831649: A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201 |
|
|
| Terminated | 2 | | US | natalizumab, TYSABRI | Biogen, Elan Pharmaceuticals | Rheumatoid Arthritis | 02/05 | | | |
NCT00516893: Natalizumab High Titer Immunogenicity and Safety |
|
|
| Completed | 2 | 113 | US | BG00002-E (natalizumab high titer), Tysabri | Biogen, Elan Pharmaceuticals | Multiple Sclerosis | 10/07 | 12/07 | | |
| Completed | 2 | 175 | US, Europe | natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate | Biogen, Elan Pharmaceuticals | Relapsing Remitting Multiple Sclerosis | 11/11 | 11/11 | | |
|
NCT01710228: Alternative Treatment Paradigm for Natalizumab Trial |
|
|
| Withdrawn | 2 | 0 | US | methylprednisolone | University of Texas Southwestern Medical Center, Teva Branded Pharmaceutical Products R&D, Inc., The University of Texas Health Science Center, Houston, University of Alabama at Birmingham, Charite University, Berlin, Germany | Multiple Sclerosis (MS) | 12/13 | 12/13 | | |
REFINE, NCT01405820 / 2010-024000-10: Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) |
|
|
| Completed | 2 | 290 | Europe | natalizumab IV, Tysabri, BG00002, natalizumab SC, IV Placebo, SC Placebo | Biogen | Relapsing-Remitting Multiple Sclerosis | 04/14 | 10/14 | | |
|
NCT01416155: Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis |
|
|
| Completed | 2 | 97 | Japan | natalizumab, Tysabri, BG00002 | Biogen | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | 12/14 | 12/14 | | |
| Terminated | 2 | 2 | Europe | natalizumab, BG00002, Tysabri | Biogen | Relapsing Multiple Sclerosis | 06/15 | 06/15 | | |
